Prostate Cancer

PROSTATE UPDATE! TrailBlazer (the Medicare contractor for Colorado) has APPROVED CyberKnife treatment for all prostate patients enrolled in an approved clinical trial! Please contact our center for more information!!!

Click here to view the updated Medicare policy approving CyberKnife treatment for prostate cancer!

If your physician is telling you that treatment of prostate cancer by CyberKnife is "unproven" or "experimental," contact us immediately.  We can provide you and your physician with the necessary clinical studies and evidence from thousands of successful prostate cancer treatments using the CyberKnife.  Click here for many of the recent clinical studies and reports about this treatment option.

What is Prostate Cancer?

The prostate is a male sex gland that is about the size of a walnut. It produces a thick fluid that is a normal component of semen in men. Prostate cancer is the most common cancer among men in the United States after non-melanoma skin cancer, and is the third leading cause of cancer-related deaths. Prostate cancer is expected to be diagnosed in 186,320 men in 2008.  Because of widespread screening efforts, the majority of newly diagnosed prostate cancers are found early when they are still confined to the prostate gland, thus the number of prostate cancer-related deaths has decreased.

How is Prostate Cancer detected?

Prostate cancer is usually detected with a combination of a prostate-specific antigen test (i.e., a PSA test, in which the levels of a protein in the blood are assessed) and digital rectal exam (DRE), where the doctor feels for any enlarged, irregular, or firm areas on the prostate. Elevated PSA levels and/or an abnormal DRE will usually prompt the doctor to perform a biopsy of the prostate. Typically during this procedure, a transrectal ultrasound (TRUS) is used to visualize the prostate and help the physician guide the biopsy needle. A prostate biopsy is usually performed in the doctor’s office with the patient under local anesthesia. The biopsy sample is then sent to a lab and assessed by a pathologist, who specializes in diagnosing diseases by examining tissue, blood and body fluids. If cancer is present in the biopsy sample, then further testing, such as a Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI), Positron Emission Tomography-CT (PET-CT) scans, or bone scans may be recommended to determine the stage of cancer.

How is Prostate Cancer treated?

For patients with early stage prostate cancer that is confined to the prostate itself, treatment options include surgery, external beam radiation therapy (EBRT), brachytherapy (LDR and HDR), CyberKnife Radiosurgery, hormonal therapy and watchful waiting. Each of these options is explained in detail below.

Radiosurgery:
Radiosurgery devices, such as the CyberKnife, offer patients a new option for the treatment of prostate cancer. The challenge that doctors face in treating prostate tumors is that the prostate moves unpredictably as air passes through the rectum and as the bladder empties and fills. Minimizing any large movements of the prostate can help reduce unnecessary irradiation of surrounding healthy tissue.  The CyberKnife is able to overcome this challenge by continuously identifying the exact location of the prostate tumor throughout the course of the treatment.

Prostate cancer surgery:
Prostate cancer surgery involves complete removal of the prostate and some of the adjacent tissues (radical prostatectomy). There are two types of surgery common for prostate cancer: open radical prostatectomy and laparoscopic prostatectomy.

Open radical prostatectomy:
There are two approaches to performing an open radical prostatectomy, a radical retropubic approach and a radical perineal approach. During a radical retropubic prostatectomy, a long incision is made in the lower abdomen and the surgeon removes the entire prostate with some surrounding tissues. Nerves in the surrounding tissues can be easily damaged during this procedure, resulting in impotence, so surgeons often use techniques to preserve the nerves around the prostate that control erections. Nerve-sparing techniques have been shown to decrease the incidence of impotence following radical prostatectomy, but there is still a high risk of impotence following surgery. The radical perineal approach involves the surgeon making an incision in the perineum, the skin between the testicles and the anus. Nerve-sparing techniques are more difficult in this approach. Patients that undergo open radical prostatectomy typically spend three to four days in the hospital and can expect to have a catheter remain in their urethra for three to four weeks to help with urination. Either surgical approach poses a significant risk of possible complications for patients, such as infection, bleeding, lengthy hospital stays, urinary side effects and impotence. In general, open prostatectomy is a highly effective modality for controlling prostate cancer, with long-term (10-15 years) overall survival ranging from as high as 97%. Urinary complications are common shortly after surgery, and in the long term urinary incontinence may occur in 5-15% of patients and impotence has been reported to occur in 50-80% of patients.

Laparoscopic prostatectomy:
Laparoscopic prostatectomy is becoming more popular because it is less invasive. During this procedure, surgeons make several small incisions in the abdomen. Instruments are inserted through the small incisions and are used to remove the prostate and surrounding tissues. There is little evidence that laparoscopic prostatectomy is superior to open surgery in its ability to control the disease but does have a reduction in complications. Laparoscopic prostatectomy may be robotic-assisted; in some reports of this method complications have been reduced relative to non-robotic prostatectomy (urinary incontinence has been reported in 1-20% of patients, and impotence rates have ranged from 17-40%). Patients who undergo laparoscopic prostatectomy typically are hospitalized for two to three days with a catheter in place in the urethra and have a shorter post-surgical recovery time compared to open surgery.

External beam radiation therapy:
Radiation therapy is a non-invasive procedure that uses radiation to kill prostate cancer cells. Prior to treatment, CT and MRI images are taken to determine the exact location of the prostate and surrounding structures. A treatment plan is then created to deliver the radiation to the prostate and some of the surrounding tissue. It is necessary to irradiate some of the surrounding healthy tissue during this treatment because there is a significant amount of variability in the day-to-day location of the prostate and because the prostate can move inside the body from the effects of gas in the rectum and fluid in the bladder, which cause uncertainties in the exact position of the prostate. Each treatment session lasts several minutes and is painless. Treatments are typically delivered on an outpatient basis, five days a week, for seven to 10 weeks. Published outcomes of prostate cancer treatment by external beam radiation therapy include long-term survival of as high as 91%. Patients may experience more rectal complications compared to surgery (10-20% of patients), urinary toxicity has been reported in 10–15% of patients, and impotence has been reported in 20–64% of patients.

Brachytherapy:
Brachytherapy is an invasive procedure that delivers radiation to the prostate from a source that is implanted within the prostate. There are two approaches to brachytherapy treatments, low dose rate (LDR) brachytherapy and high dose rate (HDR) brachytherapy.

LDR brachytherapy:
In LDR brachytherapy, small radioactive seeds about the size of a grain of rice are placed into the prostate and remain there permanently. Typically, 40 to 100 seeds are placed into the prostate through a needle, which is inserted through the skin. To relieve discomfort, the procedure is done using spinal anesthesia or general anesthesia. The procedure may require overnight hospitalization. The seeds emit low dose radiation to the prostate over several weeks or months, and the patient is radioactive while the radiation is being emitted by the seeds. LDR brachytherapy results in a high rate of long-term survival, ranging from 85-94% in published reports. Patients may experience low rates of urinary and rectal side effects (3-5%), and sexual dysfunction has been reported in 20-50% of patients. In very rare situations, the seeds have become dislodged from the prostate, enter the blood stream and migrate to other distant organs, but this does not typically pose health complications.

HDR brachytherapy:
HDR brachytherapy involves administration of high doses of radiation to the prostate over a short period of time. Typically, an HDR brachytherapy procedure involves insertion of 12 to 20 hollow needles containing catheters, which are inserted through the skin and into the prostate. Spinal anesthesia is usually given and the procedure often requires overnight hospitalization. After the catheters are in place, a CT scan and/or MRI are taken to confirm the exact location of the catheters, prostate and surrounding tissues. A treatment plan is then created and a radioactive source is placed through the catheters to allow radiation to reach the prostate. The radioactive source remains at a location in the prostate for five to 15 minutes and is then removed. Often the treatment occurs over several days and the catheters are removed after the last treatment. Studies have shown that HDR brachytherapy results in excellent local control rates (89-98% in 3-6 years after treatment) with rates of urinary, rectal and sexual function side effects that approximate those obtained with LDR brachytherapy. Nevertheless, this procedure can be painful and difficult for patients to undergo because of its invasiveness.

Hormonal therapy:
Male hormones, known as androgens, are produced normally by men and help support the growth of prostate cancer cells. The goal of hormonal therapy is to decrease the amount of these specific hormones produced, in order to control the growth of the prostate cancer cells. Hormonal therapy is usually prescribed in combination with other treatments, including external beam radiation therapy, brachytherapy or before surgery to help shrink the size of the tumor. Side effects associated with hormonal therapy can include decreased libido, impotence, hot flashes, osteoporosis and breast tenderness.

Watchful waiting:
Prostate cancer is often a slow-growing cancer. Doctors may recommend that a patient receive no immediate treatment, instead just closely monitoring the patient with PSA testing and rectal exams. Some men, especially those who are older or have other health problems, may never need prostate cancer treatments.